Natera presents 35 oncology studies at ASCO 2026, including three oral presentations on MRD-guided cancer care

Natera/Signatera

Natera presented extensive clinical evidence at ASCO 2026 showing Signatera's role in guiding treatment decisions. Key findings from the GALAXY trial demonstrated that MRD-positive patients benefited substantially from adjuvant chemotherapy while MRD-negative patients had excellent outcomes, potentially avoiding unnecessary overtreatment.

• GALAXY trial showed hazard ratio 0.3 for chemotherapy benefit in MRD-positive colorectal cancer patients.
• MRD-negative patients had excellent prognosis regardless of additional therapy, suggesting potential to de-escalate treatment.
• Data supports use of Signatera for MRD-guided adjuvant therapy decisions in colorectal cancer.